Studies have shown tirzepatide can have a greater effect on weight loss and A1C levels, but higher doses are also known to be associated with more severe stomach-related side effects like nausea, vomiting and diarrhea
However, long-term data is limited, necessitating ongoing benefits-harm analysis updates as more evidence becomes available
Glucagon receptor activation is the novel addition
Clinical trials have shown improvements in: Blood pressure Cholesterol and blood sugar levels Mobility and physical function Overall quality of life Even a 510% reduction in weight can reduce the risk of developing diabetes, heart disease, and certain cancers
Highly fermentable fibers like inulin and fructooligosaccharides can cause significantly more gas and bloating when transit time is already extended
Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages